<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466765</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol no. 2004-03</org_study_id>
    <nct_id>NCT00466765</nct_id>
  </id_info>
  <brief_title>Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting</brief_title>
  <official_title>Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brava</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study is to determine whether use of a negative pressure&#xD;
      external soft-tissue expansion system pre-operatively and post-operatively improves and&#xD;
      secures graft survival in autologous fat micro grafting breast augmentation and&#xD;
      reconstruction procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedure:&#xD;
&#xD;
      Urine pregnancy test will be performed before each designated procedure in the study.&#xD;
      Patients will be questioned about underlying renal disease and excluded if existent.&#xD;
&#xD;
      Pre-operative/baseline digital or 35mm photos will be obtained utilizing the standard&#xD;
      criteria as performed routinely by plastic and reconstructive surgeons before any surgical&#xD;
      procedure. Oblique, frontal and sagittal views will be stored in protected files.&#xD;
&#xD;
      Optional: Patients will have a preoperative breast MRI with the contrasting agent Gadolinium,&#xD;
      utilizing a 1.5 Tesla MRI machine and breast coils unless status post breast cancer where no&#xD;
      pre-operative MRI is needed. All readings will be performed by board certified radiologists.&#xD;
&#xD;
      Brava domes will be worn bilaterally 3-4 weeks before surgery for 10-12 hours per day, 7 days&#xD;
      a week with 24 hour wear for the final 72 hours (3 days) before surgery. Patients will be&#xD;
      required to adhere to the dome cleaning process specified by the manufacturer. This is&#xD;
      prudent for hygienic reasons and to reduce skin irritation and infections. The domes are for&#xD;
      single patient use only. Pressure will range from 15 mmHg to 105mmHg and will be achieved and&#xD;
      regulated by either SmartBox, bulb syringe and/or Brava Turbo devices. This will open up the&#xD;
      tissue planes and maximally expand the recipient breast in preparation for graft insertion.&#xD;
&#xD;
      Institutional Review Board approval will be obtained and all patients will be properly&#xD;
      advised of their rights via signed Informed Consents.&#xD;
&#xD;
      All patients will be assessed by board certified plastic and reconstructive surgeons for&#xD;
      autologous fat harvesting sites. Preoperative sedation with IV sedation and/or oral sedation&#xD;
      is recommended. Preoperative antibiotics, such as Keflex or similar drug, will be&#xD;
      administered before surgery. Sterile drape and prep of the fat harvesting sites will be&#xD;
      carried out.&#xD;
&#xD;
      Tumescent anesthetic solution will be prepared by diluting 50cc's of 1% lidocaine with&#xD;
      1/100,000 units of epinephrine with 1000cc's of Ringers Lactate solution and will be&#xD;
      instilled with a 14-gauge infusion infiltration cannula into the areas of fat harvesting.&#xD;
&#xD;
      Gentle, low vacuum pressure manual liposuction will be performed to avoid damaging the fat&#xD;
      cells. Liposuction will be performed in a standard fashion using 12G &amp; 12 side holes&#xD;
      harvesting cannulas and connected to syringes that maintain a controlled constant low vacuum&#xD;
      pressure of 300 mmHg (preferably using the K-VAC (Vacuum Assisted Device) syringe). The&#xD;
      aspirate will be purged from the syringes into collection bags using atraumatic nonclogging&#xD;
      valves (preferably the AT-Valve) or 3 way stopcocks. Once filled, the bags will be spun at&#xD;
      low speed (&lt;1000 rpm) to separate fat from serum (and free of oil, if any). The infranatant&#xD;
      serum will be drained and the cellular fat supernatant will be concentrated in the bags and&#xD;
      directly re-injected into the breasts. Depending upon the volume correction required and the&#xD;
      recipient space available, 100 to 500 ml of gently centrifuged (non-packed) fat will be&#xD;
      injected per breast.&#xD;
&#xD;
      The recipient breast will be marked carefully prior to infiltration of anesthetics to&#xD;
      determine the preferred graft distribution pattern and to select 9-18 graft insertion sites&#xD;
      (circumareolar, inframammary, axillary and at the circumference of the breast). The skin will&#xD;
      be infiltrated at the graft insertion sites with Naropin 2% (ropivacine).&#xD;
&#xD;
      After the recipient site is anesthetized, puncture sites will be made with a 14-gauge needle.&#xD;
      A 14-gauge blunt tip cannula or similar cannula connected to a 3 ml syringe is used to gently&#xD;
      inject small droplets distally first and then subsequently proximally as the cannula is&#xD;
      withdrawn. Repeated passes at multiple levels in a radial fashion are performed through each&#xD;
      of the puncture sites such that the grafts droplets are laid down in a criss-crossing pattern&#xD;
      and at multiple planes. Avoid the glandular tissue by remaining in the subcutaneous plane and&#xD;
      if more volume is needed and is available proceed to fill the subglandular, intramuscular and&#xD;
      submuscular planes. Incision sites are covered with sterile band aids applied to skin. Gentle&#xD;
      conforming dressings will be applied to breast.&#xD;
&#xD;
      Elastic garments will be placed on harvest site. Postoperative instructions are handed to&#xD;
      each patient. Patient will begin wearing the Brava System, with the SmartBox device only, 18&#xD;
      hours post-operative as a stabilization device. For the first three (3) days the system is&#xD;
      worn 24 hours a day or as to the maximum tolerated. If the patient notes pain, the system may&#xD;
      be removed and replaced a few hours later. The System is then worn 10 to 12 hours a day for&#xD;
      one additional week (7 days). Then the patient may choose to proceed with a prolonged&#xD;
      intermittent wear of 10 hours per day for 10 - 14 weeks.&#xD;
&#xD;
      Follow-up will include: A call from the surgical team within 24 hours after surgery. An&#xD;
      office follow up visit within 48-72 hours of surgery and follow-up appointment in 6 months.&#xD;
      More office follow up visits in the interim are recommended but not mandatory.&#xD;
&#xD;
      A one-year post grafting mammogram will be recommended to all women over the age of 40.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digital photographic interpretation by Board Certified Plastic Surgeon or Radiologist.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's satisfaction with cosmetic and reconstructive result.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">589</enrollment>
  <condition>Mammaplasty</condition>
  <condition>Mastectomy</condition>
  <condition>Lumpectomy</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use Brava system for pre-expansion of breast prior to fat grafting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brava Autologous Fat Transfer System</intervention_name>
    <description>Number of procedures is based on patient need</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Brava System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Female volunteers between the ages of 18 and 80 years of age and weighing between 100- 275&#xD;
        lbs may be enrolled in the study. Ages 16 to 18 with developmental deformities may be&#xD;
        enrolled with parental consent.&#xD;
&#xD;
          -  Post implant removal with subcutaneous defect&#xD;
&#xD;
          -  Post lumpectomy patients with or without radiation therapy with asymmetrical defect&#xD;
&#xD;
          -  Post mastectomy with or without radiation therapy&#xD;
&#xD;
          -  Post flap reconstruction with asymmetry or contour defect&#xD;
&#xD;
          -  Primary breast augmentation&#xD;
&#xD;
          -  Primary Post-mastectomy breast reconstruction&#xD;
&#xD;
          -  Breast asymmetry&#xD;
&#xD;
          -  Other congenital malformation of the breast such as constricted breasts, tubular&#xD;
             breast, tuberous breasts, pectus associated deformities and Poland's Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following volunteers must be excluded from the study:&#xD;
&#xD;
          -  A volunteer who has a positive pregnancy test&#xD;
&#xD;
          -  A volunteer who has a pacemaker or aneurysm clips&#xD;
&#xD;
          -  A volunteer who has had a cardiac stent placed within the last two months&#xD;
&#xD;
          -  A volunteer who is claustrophobic&#xD;
&#xD;
          -  A volunteer with a known, current substance abuse&#xD;
&#xD;
          -  A volunteer with a history of silicone allergy&#xD;
&#xD;
          -  A volunteer with a history of Gadolinium allergy (if MRI performed)&#xD;
&#xD;
          -  A volunteer with a history of Lidocaine allergy&#xD;
&#xD;
          -  A volunteer with a bleeding diathesis&#xD;
&#xD;
          -  Untreated breast cancer&#xD;
&#xD;
          -  A volunteer who smokes cigarettes or who has a history of smoking within the past&#xD;
             three (3) months.&#xD;
&#xD;
          -  Medical Conditions including Sever Hypertension, Renal disease, steroid dependant&#xD;
             asthma, immuno-suppressed disease, Systemic Lupus, uncontrolled diabetes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Khouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brava LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roger K Khouri, MD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Breast Center, Medical Office of Roger Khouri MD</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://brava.com</url>
    <description>Information on the Brava System</description>
  </link>
  <link>
    <url>http://www.miamibreastcenter.com</url>
    <description>Roger K Khouri, MD information</description>
  </link>
  <reference>
    <citation>Coleman SR, Saboeiro AP. Fat grafting to the breast revisited: safety and efficacy. Plast Reconstr Surg. 2007 Mar;119(3):775-85; discussion 786-7.</citation>
    <PMID>17312477</PMID>
  </reference>
  <reference>
    <citation>Rigotti G, Marchi A, Gali√® M, Baroni G, Benati D, Krampera M, Pasini A, Sbarbati A. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007 Apr 15;119(5):1409-1422. doi: 10.1097/01.prs.0000256047.47909.71.</citation>
    <PMID>17415234</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <disposition_first_submitted>April 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 5, 2015</disposition_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fat Grafting</keyword>
  <keyword>Breast Augmentation</keyword>
  <keyword>Liposuctioned Fat Transfer</keyword>
  <keyword>Lumpectomy</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Micromastia</keyword>
  <keyword>Asymmetry</keyword>
  <keyword>Post Lumpectomy Filling Defects</keyword>
  <keyword>Post implant removal filling defect</keyword>
  <keyword>Post Mastectomy</keyword>
  <keyword>Autologous Fat Transfer</keyword>
  <keyword>Tubular breasts</keyword>
  <keyword>Tuberous breasts</keyword>
  <keyword>Constricted breasts</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

